Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

Stock Information for Citius Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Oncology Inc.

Exagen Inc. to Participate in Fourth Quarter Investor Conferences
Exagen Inc. Reports Strong Q3 2025 Results
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025
Exagen Inc. to Participate in Third Quarter Investor Conferences
Exagen Inc. Reports Strong Q2 2025 Results
Exagen Inc. Appoints Chas McKhann to Board of Directors
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.